Save the Children and GlaxoSmithKline launched a new partnership to save the lives of a million of the poorest children in the world. This unique collaboration will see the two organizations, sharing expertise, resources, and influence to tackle some of the leading causes of child mortality.
Among the key initiatives are the increased production and distribution of a life-saving product for newborn infection and the roll-out of a new antibiotic powder to help children fight pneumonia — one of the main killers of children under five.
For the first time, Save the Children will be involved in helping GSK to research and develop medicines for children, with a seat on a new pediatric R&D board to accelerate progress on innovative life-saving interventions for children, and to identify ways to ensure the widest possible distribution in the developing world. GSK will be able to leverage Save the Children's child health expertise and on the ground experience to reach children with basic healthcare in the poorest, most remote communities.
The GSK and Save the Children partnership will also focus on expanding vaccine services to the poorest children, increasing investment in health workers, and a low-cost nutritional product to help combat child malnutrition.
The first phase of the GSK supported programs will run in the Democratic Republic of Congo and Kenya, with future programs planned for other countries in Sub-Saharan Africa, Asia and Latin America.
While good progress has been made in recent years, almost seven million children died in 2011 through lack of access to basic healthcare, vaccines or nutritious food. Through these and other initiatives, the partnership aims to help save the lives of one million children in the next five years.
GSK is one of the world’s leading research-based pharmaceutical and healthcare companies. GSK is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.